Oncotelic Therapeutics, Inc.
OTLC
$0.056
-$0.0024-4.11%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -100.00% | -- | -- | -- | -- |
| SG&A Expenses | -45.61% | -71.01% | -57.89% | -88.18% | -85.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -52.92% | -71.39% | -62.43% | -88.02% | -85.50% |
| Operating Income | 49.27% | 76.02% | 67.00% | 89.27% | 86.54% |
| Income Before Tax | 61.47% | 88.99% | -188.15% | -275.47% | -258.50% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 61.47% | 88.99% | -188.15% | -275.47% | -258.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -15.06% | -14.81% | 11.76% | -27.59% | -43.99% |
| Net Income | 62.60% | 90.72% | -182.66% | -255.11% | -245.01% |
| EBIT | 49.27% | 76.02% | 67.00% | 89.27% | 86.54% |
| EBITDA | 87.65% | 93.85% | 78.52% | 89.48% | 86.63% |
| EPS Basic | 64.38% | 91.25% | -178.40% | -248.51% | -242.22% |
| Normalized Basic EPS | 54.55% | 79.59% | 68.52% | 82.50% | 74.81% |
| EPS Diluted | 58.44% | 91.25% | -178.40% | -248.51% | -242.22% |
| Normalized Diluted EPS | 54.55% | 79.59% | 68.52% | 82.50% | 74.81% |
| Average Basic Shares Outstanding | 2.76% | 2.88% | 3.43% | 3.98% | 3.06% |
| Average Diluted Shares Outstanding | 2.76% | 2.88% | 3.43% | 3.98% | 3.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |